| Identification | Back Directory | [Name]
VU 0357017 hydrochloride | [CAS]
1135242-13-5 | [Synonyms]
CS-2319
VU0357017
CID 25010775
SID 56353039
ML071 hydrochloride
VU 0357017 hydrochloride
VU0357017 monohydrochloride
Ethyl 4-(2-(2-methylbenzamido)ethylamino)piperidine-1-carboxylate hydrochloride
VU0-357017;VU 0357017;CID-25010775; VU-0357017 HYDROCHLORIDE; VU 0357017 HYDROCHLORIDE
4-[[2-[(2-Methylbenzoyl)aMino]ethyl]aMino]-1-piperidinecarboxylic Acid Ethyl Ester Hydrochloride
4-[[2-[(2-Methylbenzoyl)amino]ethyl]amino]-1-piperidinecarboxylic acid ethyl ester monohydrochloride | [Molecular Formula]
C18H28ClN3O3 | [MDL Number]
MFCD17215959 | [MOL File]
1135242-13-5.mol | [Molecular Weight]
369.9 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO: ≥10mg/mL | [form ]
powder | [color ]
white to off-white | [InChI]
1S/C18H27N3O3.ClH/c1-3-24-18(23)21-12-8-15(9-13-21)19-10-11-20-17(22)16-7-5-4-6-14(16)2;/h4-7,15,19H,3,8-13H2,1-2H3,(H,20,22);1H | [InChIKey]
XKJQVUIXSBOCPP-UHFFFAOYSA-N | [SMILES]
Cl.CCOC(=O)N1CCC(CC1)NCCNC(=O)c2ccccc2C |
| Hazard Information | Back Directory | [Uses]
VU0357017 is a subtype-selective M1 muscarinic acetylcholine allosteric agonist. VU0357017 has a potency of 200 nM and Achmax of 81% and had no activity at M2-M5 up to the highest concentrations tested and also had little or no detectable antagonist activity at any other mAChR subtype at concentrations over 2 orders of magnitude higher than those required to activate M1 or activity at a large panel of GPCRs, ion channels, and transporters. In contrast, TBPB inhibited responses to ACh at each of the other mAChR subtypes. VU0357017 was active in reversing cognitive deficits induced by Scopolamine (S200000) in a preclinical rodent model. | [Biological Activity]
VU0357017 is a subtype-selective M1 muscarinic acetylcholine allosteric agonist. VU0357017 has a potency of 200 nM and Achmax of 81% and had no activity at M2-M5 up to the highest concentrations tested and also had little or no detectable antagonist activity at any other mAChR subtype at concentrations over 2 orders of magnitude higher than those required to activate M1 or activity at a large panel of GPCRsion channelsand transporters. In contrastTBPB inhibited responses to ACh at each of the other mAChR subtypes. VU0357017 was active in reversing cognitive deficits induced by scopolamine in a preclinical rodent model. | [in vivo]
VU0357017 (1-10 mg/kg, i.p.) reverses scopolamine-induced disruption of the contextual fear conditioning response[2].
| Animal Model: | Male Sprague?Dawley rats (380-420 g) were pretreated with scopolamine[2] | | Dosage: | 1, 3, 10 mg/kg | | Administration: | A single i.p. | | Result: | Produced a significant reversal of the scopolamine-induced deficits at a dose of 10 mg/kg. |
| [IC 50]
mAChR1 | [storage]
+4°C |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
|